These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

60 related articles for article (PubMed ID: 121572)

  • 1. Detection of proteolytic (C 3-cleaving) activity on mouse mastocytoma (P 815) cells and other mouse cell lines by formation of cell contact with C 3-carrying mouse lymphocytes.
    Dierich MP; Schulz T; Yefenof E; Klein G
    Eur J Immunol; 1979 Dec; 9(12):928-32. PubMed ID: 121572
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasminogen activation by normal B lymphocytes, a function associated with the cell membrane.
    Maillard JL; Favreau C
    J Immunol; 1981 Mar; 126(3):1126-30. PubMed ID: 6161960
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A simple rosette assay for demonstration of complement receptor sites using complement-coated zymosan beads.
    Huber Ch; Wigzell H
    Eur J Immunol; 1976 Jun; 5(6):432-5. PubMed ID: 1086242
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interaction of antigen-specific T cell factors with unique "receptors" on the surface of mast cells: demonstration in vitro by an indirect rosetting technique.
    Kops SK; Ratzlaff RE; Meade R; Iverson GM; Askenase PW
    J Immunol; 1986 Jun; 136(12):4515-24. PubMed ID: 2423595
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Qualitative and quantitative assessment of C3-receptor reactivities on lymphoid and phagocytic cells.
    Schmitt M; Mussel HH; Dierich MP
    J Immunol; 1981 May; 126(5):2042-7. PubMed ID: 7217681
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The third component of complement (C3) bound to tumor target cells enhances their sensitivity to killing by activated macrophages.
    Bara S; Lint TF
    J Immunol; 1987 Feb; 138(4):1303-9. PubMed ID: 3100634
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Humoral mechanisms of in vitro inhibition of mouse lymphocyte immunoreactivity by mastocytoma P815 cells].
    Medvedev AE
    Biull Eksp Biol Med; 1988 Jun; 105(6):701-3. PubMed ID: 2968820
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human natural killer-like activity against mouse spleen cells.
    Yamamoto JK; Blalock JE; Johnson HM
    Eur J Immunol; 1982 Mar; 12(3):222-7. PubMed ID: 7047174
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Membrane receptors of mouse leukocytes. I. Two types of complement receptors for different regions of C3.
    Rabellino EM; Ross GD; Polley MJ
    J Immunol; 1978 Mar; 120(3):879-85. PubMed ID: 632590
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monoclonal antibodies to mouse complement receptor type 1 (CR1). Their use in a distribution study showing that mouse erythrocytes and platelets are CR1-negative.
    Kinoshita T; Takeda J; Hong K; Kozono H; Sakai H; Inoue K
    J Immunol; 1988 May; 140(9):3066-72. PubMed ID: 2966205
    [TBL] [Abstract][Full Text] [Related]  

  • 11. B lymphocytes and macrophages release cell membrane deposited C3-fragments on exosomes with T cell response-enhancing capacity.
    Papp K; Végh P; Prechl J; Kerekes K; Kovács J; Csikós G; Bajtay Z; Erdei A
    Mol Immunol; 2008 Apr; 45(8):2343-51. PubMed ID: 18192019
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lymphocyte binding of fluid phase mouse C3b.
    Papamichail M; Pepys MB
    Immunology; 1979 Mar; 36(3):461-70. PubMed ID: 374253
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of protease inhibitors on human monocyte IgG Fc receptor II. Evidence that serine esterase activity is essential for Fc gamma RII-mediated binding.
    van de Winkel JG; Jansze M; Capel PJ
    J Immunol; 1990 Sep; 145(6):1890-6. PubMed ID: 2144012
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The detection of membrane-associated complement components (C 3 and C 4) on circulating human normal and leukemic leukocytes and on cultured cells with monkey erythrocytes.
    Burns GF; Cawley JC
    Eur J Immunol; 1979 Oct; 9(10):791-6. PubMed ID: 118035
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytotoxic activity of human lymphocyte plasma membranes.
    Ferluga J; Friou GJ; Allison AC
    Clin Exp Immunol; 1976 Aug; 25(2):347-51. PubMed ID: 821684
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunosuppression induced in vitro by mastocytoma tumor cells and cell-free extracts.
    Kamo I; Patel C; Kateley J; Friedman H
    J Immunol; 1975 Jun; 114(6):1749-56. PubMed ID: 805176
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A subpopulation of human B lymphocytes that rosette with mouse erythrocytes.
    Forbes IJ; Zalewski PD
    Clin Exp Immunol; 1976 Oct; 26(1):99-107. PubMed ID: 1087215
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Capacity of different cell types to stimulate cytotoxic T lymphocyte precursor cells in the presence of interleukin 2.
    Dröge W; Moyers C; Wehrmaker A; Schmidt H; Panknin S; Männel D; Falk W
    J Immunol; 1984 Jun; 132(6):2749-59. PubMed ID: 6233360
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evidence for a T suppressor cell-inducing antigenic determinant shared by ADJ-PC-5 plasmacytoma and syngeneic BALB/c spleen cells.
    Kloke O; Haubeck HD; Kölsch E
    Eur J Immunol; 1986 Jun; 16(6):659-64. PubMed ID: 2424769
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cell growth-dependent variation in the sensitivity of human and mouse tumor cells to complement-mediated killing.
    Ohanian SH; Yamazaki M; Schlager SI; Faibisch M
    Cancer Res; 1983 Feb; 43(2):491-5. PubMed ID: 6401218
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.